Latest Headlines

  1. Rancho BioSciences Launches OmicsHQ™: A Comprehensive, Curated, Multi-Omics Data Platform Built To Accelerate Drug Discovery 5/19/2026

    Today Rancho BioSciences, the premier tech-enabled data science partner for biopharma, announced the launch of OmicsHQTM, a unified catalog of expertly curated, standardized multi-omics datasets designed for immediate use in research, drug discovery, and AI/ML model development. The company is launching the product at BioIT World Conference & Expo, May 19, 2026, Boston, MA.

  2. Genedata Introduces AI-Native CMC Platform To Accelerate Drug Development And Manufacturing 5/19/2026

    Genedata, a Danaher company, and the leading provider of enterprise software solutions for biopharma R&D, today announced the launch of Genedata Vico™, an AI–native solution to accelerate CMC processes by enabling data-driven experimentation, process monitoring, and predictive risk assessment — helping organizations strengthen regulatory readiness and reduce development delays.

  3. QIAGEN To Advance AI-Driven Drug Discovery With Graph-Based AI And Curated Bioinformatics Knowledge With NVIDIA 5/19/2026

    QIAGEN announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more effectively in drug discovery.

  4. U.S. FDA Accepts Viatris New Drug Application For Fast-Acting Meloxicam For The Treatment Of Moderate-To-Severe Acute Pain 5/18/2026

    Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain.

  5. Piramal Pharma Solutions Announces Partnership With Botanix To Support Drug Substance Development 5/18/2026

    Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has entered a manufacturing and supply arrangement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT) ("Botanix"), a commercial dermatology company.

  6. Harbour BioMed Announces Promising Preclinical Data For LET003, Its First AI-Enabled Drug Candidate 5/17/2026

    Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced preclinical data for LET003, its first next-generation ACVR2A/2B-targeting monoclonal antibody developed using the Hu-mAtrIx™ platform.

  7. The Solubility Company And Persist AI Unveil Strategic Partnership To Enable Microgram-Level Formulation Development And Bridge The Data Gap In AI-Driven Drug Formulation 5/13/2026

    The Solubility Company, the pioneer of ultra-low sample solubility measurement, and Persist AI, an AI-Driven automated Pharma Formulation Cloud Lab, today announced a strategic collaboration to launch the first fully automated SPA® platform (single particle analysis).

  8. Creatv Bio Opens CLIA-Certified Laboratory To Support Oncology Drug Development 5/13/2026

    Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a liquid biopsy-based cancer diagnostic testing company, recently opened its full service CLIA-certified laboratory in Monmouth Junction, NJ.

  9. OpenBind Releases First Open Dataset And AI Model For Drug Discovery 5/13/2026

    Researchers from the University of Oxford, as part of the OpenBind consortium, have published a new dataset and predictive AI model, strengthening the data foundations needed for AI in drug discovery.

  10. Nexentis Technologies Announces Optimization Of Hit Molecule At MitoCareX Bio Representing Key Drug Discovery Milestone 5/13/2026

    Nexentis Technologies Inc. ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd.